Topics

Glioblastoma | Treatment | Clinical trials | Temozolomide

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Temozolomide

2024

Bhaskaran D, Savage J, Patel A, Collinson F, Mant R, Boele F, Brazil L, Meade S, Buckle P, Lax S, Billingham L, Short SC.
A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
BMC Cancer. 2024 Jan 15;24(1):83. doi: 10.1186/s12885-023-11792-4. PMID: 38225549. Interventional study protocol. ˍ

Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto Y, Imai R, Kuranari Y, Tohmoto K, Hasegawa Y, Akasaki Y, Murayama Y, Miyake K, Sasaki H.
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
J Neurooncol. 2024 Jan 31. doi: 10.1007/s11060-023-04544-8. PMID: 38291182. Interventional study. ˍ

Anvari K, Seilanian Toussi M, Saghafi M, Javadinia SA, Saghafi H, Welsh JS.
Extended dosing (12 cycles) vs conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high-grade gliomas: a randomized, single-blind, two-arm, parallel-group controlled trial.
Front Oncol. 2024 May 7;14:1357789. doi: 10.3389/fonc.2024.1357789. PMID: 38774410. Interventional study. ˍ

*Sharifian A, Kazemian A, Farzin M, Amirkhani N, Farazmand B, Naderi S, Khalilian A, Pourrashidi A, Amjad G, Kolahdouzan K, Abyaneh R, Jablonska PA, Ghalehtaki R.
Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.
Neurooncol Adv. 2024 Nov 14;6(1):vdae195. doi: 10.1093/noajnl/vdae195. PMID: 39664679. Interventional study. ˍ

2025

Geurts M, Berchtold L, Koenig F, Nabors B, Reardon DA, Tonn JC, Stupp R, Gorlia T, Weller M, Preusser M; EORTC Brain Tumor Group.
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?
Neurooncol Pract. 2025 Jan 17;12(2):291-300. doi: 10.1093/nop/npaf006. PMID: 40110070. Observational study. ˍ

Chen B, Alder J.
A systematic review of immunotherapies in combination with temozolomide as treatment for glioblastoma.
Cancer Treat Res Commun. 2025 Feb 24;43:100888. doi: 10.1016/j.ctarc.2025.100888. PMID: 40023003. Review. ˍ

Brown NF, McBain C, Brazil L, Peoples S, Jefferies S, Harris F, Vinayan A, Plaha P, Brooks C, Hussain S, Dutton SJ, Cook J, Ng SM, Levy S, Coutts T, Mulholland P.
Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial.
Neurooncol Adv. 2025 May 26;7(1):vdaf032. doi: 10.1093/noajnl/vdaf032. PMID: 40800123. Interventional study. ˍ

Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, Rahman M, Tran DD.
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study.
Med. 2025 Jun 3:100708. doi: 10.1016/j.medj.2025.100708. PMID: 40466642. Interventional study. ˍ

Nakai K, Kumada H, Matsumoto Y, Baba K, Murakami M, Ishida T, Saito T, Nakamura M, Numajiri H, Mizumoto M, Sugii N, Miki S, Ishikawa E, Maruo K, Takemura M, Hashimoto K, Takahashi T, Hayashi T, Sakurai H.
Boron neutron capture therapy (BNCT) phase I clinical trial for newly diagnosed glioblastoma by newly developed accelerator at University of Tsukuba.
Appl Radiat Isot. 2025 Sep 3;226:112152. doi: 10.1016/j.apradiso.2025.112152. PMID: 40945116.Interventional study protocol. ˍ

2026

Limon D, Bokstein F, Blumenthal DT, Ram Z, Grossman R.
Prospective randomized trial of tumor-treating fields with chemoradiation in newly diagnosed glioblastoma.
Neurooncol Adv. 2026 Apr 24;8(1):vdag106. doi: 10.1093/noajnl/vdag106. PMID: 42239656. Trial registration ID: NCT03869242. ˍ